Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Kras Tcr-Transduced Pbl Digestive System Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Kras Tcr-Transduced Pbl Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Kras Tcr-Transduced Pbl Small Intestine Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Cervical Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Colon Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Exocrine Pancreatic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Gastric Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Hematopoietic And Lymphoid Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Malignant Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Uterine Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1601 to 1625 of 3,272 assets

PreviousPage 65 of 131Next